Consensus Crossject

Stocks

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris 02:55:00 17/10/26 am AEDT			5-day change	1st Jan Change
1.266 ^EUR	-3.06%		-4.09%	-42.19%

13/10	Crossject: No market launch of Zepizure before H127 at best	AL
25/09	Crossject: H126. Quid novi sub sole? Not much.	AL

Evolution of the Average Target: Crossject

Evolution of the Target Price: Crossject

Changes in Analyst Recommendations: Crossject

336dcdcca3c77f627e.MU-gSiMEhA62KNAq66Y_QBqm78081P-JVHmtPTD8m2w.eCzYG3FIxz3zR5xfuNBcB26TtZ5yuLX9FjXmVF-b7zpcDpQOZjLPQPVlsw~6fa011253377308b8df3749db88869a8

Analysts' recommendations: Crossject

13/10	Crossject: No market launch of Zepizure before H127 at best	AL
25/09	Crossject: H126. Quid novi sub sole? Not much.	AL
27/05	Crossject: The last round of financing?	AL
31/03	Crossject: Integrating the FY25 numbers	AL
26/03	Crossject: FY25 results: no big change.	AL
17/11	Crossject: Yet another round of financing	AL
26/06/25	Crossject: Invest Securities Upgrades to 'Buy' Following Successful Capital Increase
09/06/25	Crossject: Here we are for the announced capital increase	AL
21/05/25	Crossject: Another capital increase in the pipe…	AL
08/05/25	Crossject: Back to life?	AL
30/03/25	Crossject: Integrating the FY24 numbers.	AL
28/03/25	Crossject: FY24 and outlook: long is the road…	AL
11/02/25	Crossject: A complex financing given the amounts involved	AL
11/12/24	Crossject: An unsurprising additional financing round.	AL
08/10/24	Crossject: H1 24: not yet meaningful	AL
25/09/24	Crossject: H1 24: no real surprise, but a glimpse of disappointment	AL
18/07/24	Crossject: We are still believers	AL
05/06/24	Crossject: Success of the capital increase	AL
02/05/24	Crossject: We welcome the securing of the group’s financial needs	AL
03/04/24	Crossject: Patience is a virtue… hopefully	AL
29/02/24	Crossject: Invest Securities slightly reduces its target
28/02/24	Crossject: Securing the financing needs	AL
08/02/24	Crossject: No news is not always good news...	AL
06/01/24	Crossject : Marketing initiative in the US	AL
03/01/24	Crossject : A new distribution agreement in Northern Europe	AL

More recommendations

Drug Delivery Systems

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
CROSSJECT	-	+227.8%
ABBOTT LABORATORIES		+15.09%
MEDTRONIC PLC		+10.41%
STRYKER CORPORATION		+23.06%
ESSILORLUXOTTICA		+43.42%
CENCORA, INC.		+7.85%
HOYA CORPORATION		+17.74%
BECTON, DICKINSON AND COMPANY		+1.21%
IDEXX LABORATORIES, INC.		+25.9%
DEXCOM, INC.		+12.11%
Average		+38.46%
Weighted average by Cap.		+17.75%